Do analysts prefer OABI or NAUT?

Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 348.43%. Given Nautilus Biotechnology's higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than OmniAb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OmniAb 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Nautilus Biotechnology (NAUT) Competitors

$0.89 +0.00 (+0.22%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.90 +0.01 (+1.01%)

As of 08/14/2026 07:34 PM Eastern

Compare

NAUT vs. PACB, SLP, LAB, TKNO, and OABI

Should you buy Nautilus Biotechnology stock or one of its competitors? Nautilus Biotechnology's main competitors and comparable companies include Pacific Biosciences of California (PACB), Simulations Plus (SLP), Standard BioTools (LAB), Alpha Teknova (TKNO), and OmniAb (OABI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Nautilus Biotechnology (NASDAQ:NAUT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

50.7% of Nautilus Biotechnology shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Nautilus Biotechnology currently has a consensus target price of $4.00, suggesting a potential upside of 348.43%. Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 59.42%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, research analysts clearly believe Nautilus Biotechnology is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Nautilus Biotechnology and Nautilus Biotechnology both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.68 beat Nautilus Biotechnology's score of 0.43 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Pacific Biosciences of California	Positive

Nautilus Biotechnology has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Pacific Biosciences of California	$160.01M	2.23	-$546.38M	-$0.43	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -82.49%. Nautilus Biotechnology's return on equity of -37.58% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Summary

Nautilus Biotechnology beats Pacific Biosciences of California on 8 of the 13 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Simulations Plus has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Simulations Plus had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for Nautilus Biotechnology. Simulations Plus' average media sentiment score of 1.18 beat Nautilus Biotechnology's score of 0.43 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Overall Sentiment
Simulations Plus	Positive
Nautilus Biotechnology	Neutral

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Simulations Plus has a net margin of 9.88% compared to Nautilus Biotechnology's net margin of 0.00%. Simulations Plus' return on equity of 13.50% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Simulations Plus presently has a consensus price target of $17.25, indicating a potential downside of 5.99%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 348.43%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nautilus Biotechnology has lower revenue, but higher earnings than Simulations Plus. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.69	-$64.72M	$0.40	45.88
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Summary

Simulations Plus beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Standard BioTools has a net margin of 100.36% compared to Nautilus Biotechnology's net margin of 0.00%. Standard BioTools' return on equity of -7.57% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Standard BioTools has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Nautilus Biotechnology has lower revenue, but higher earnings than Standard BioTools. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.28	-$74.90M	$0.22	3.24
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

In the previous week, Standard BioTools had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Standard BioTools and 2 mentions for Nautilus Biotechnology. Standard BioTools' average media sentiment score of 0.64 beat Nautilus Biotechnology's score of 0.43 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Overall Sentiment
Standard BioTools	Positive
Nautilus Biotechnology	Neutral

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Standard BioTools currently has a consensus target price of $1.35, suggesting a potential upside of 89.50%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 348.43%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Standard BioTools beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Alpha Teknova currently has a consensus price target of $7.50, indicating a potential upside of 2.88%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 348.43%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Teknova has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Alpha Teknova had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Alpha Teknova and 2 mentions for Nautilus Biotechnology. Alpha Teknova's average media sentiment score of 0.78 beat Nautilus Biotechnology's score of 0.43 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Positive
Nautilus Biotechnology	Neutral

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nautilus Biotechnology has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Alpha Teknova has higher revenue and earnings than Nautilus Biotechnology. Alpha Teknova is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	9.65	-$17.26M	-$0.31	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Summary

Alpha Teknova beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to OmniAb?

OmniAb (NASDAQ:OABI) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

OmniAb has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 348.43%. Given Nautilus Biotechnology's higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nautilus Biotechnology has a net margin of 0.00% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Nautilus Biotechnology has lower revenue, but higher earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	26.21	-$64.78M	-$0.36	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

In the previous week, OmniAb had 11 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 13 mentions for OmniAb and 2 mentions for Nautilus Biotechnology. OmniAb's average media sentiment score of 0.60 beat Nautilus Biotechnology's score of 0.43 indicating that OmniAb is being referred to more favorably in the media.

Company	Overall Sentiment
OmniAb	Positive
Nautilus Biotechnology	Neutral

72.1% of OmniAb shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

OmniAb beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.26M	$9.66B	$7.04B	$13.09B
Dividend Yield	N/A	1.46%	2.57%	10.45%
P/E Ratio	-1.98	60.32	268.81	25.27
Price / Sales	N/A	105.52	562.07	70.86
Price / Cash	N/A	26.25	70.48	50.90
Price / Book	0.87	37.50	12.91	6.24
Net Income	-$59M	$56.66B	$3.45B	$347.60M
7 Day Performance	-0.90%	0.30%	1.11%	1.06%
1 Month Performance	-48.74%	1.38%	1.33%	0.81%
1 Year Performance	25.18%	17.34%	62.44%	20.90%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.9718 of 5 stars	$0.89 +0.2%	$4.00 +348.4%	+23.6%	$113.26M	N/A	N/A	130	Short Interest Increase
PACB Pacific Biosciences of California	1.5295 of 5 stars	$1.44 +1.4%	$1.83 +27.3%	-6.5%	$441.05M	$160.01M	N/A	730	Analyst Upgrade Gap Down
SLP Simulations Plus	1.0389 of 5 stars	$18.35 +0.2%	$17.25 -6.0%	+29.2%	$370.32M	$79.18M	45.88	160	News Coverage Positive News Short Interest Increase
LAB Standard BioTools	3.0323 of 5 stars	$0.82 -5.3%	$1.35 +64.5%	-41.6%	$338.14M	$85.33M	4.10	620
TKNO Alpha Teknova	1.8758 of 5 stars	$5.52 +4.2%	N/A	+51.9%	$284.15M	$40.52M	N/A	240	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, SLP, LAB, TKNO, and OABI

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Summary

How does Nautilus Biotechnology compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, SLP, LAB, TKNO, and OABI

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Do institutionals and insiders have more ownership in NAUT or PACB?

Which has more volatility & risk, NAUT or PACB?

Do analysts prefer NAUT or PACB?

Does the media favor NAUT or PACB?

Which has stronger earnings & valuation, NAUT or PACB?

Is NAUT or PACB more profitable?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Which has more volatility & risk, SLP or NAUT?

Does the media refer more to SLP or NAUT?

Do insiders and institutionals believe in SLP or NAUT?

Is SLP or NAUT more profitable?

Do analysts prefer SLP or NAUT?

Which has better earnings and valuation, SLP or NAUT?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Is LAB or NAUT more profitable?

Which has more volatility and risk, LAB or NAUT?

Which has better valuation and earnings, LAB or NAUT?

Does the media favor LAB or NAUT?

Do insiders & institutionals hold more shares of LAB or NAUT?

Do analysts prefer LAB or NAUT?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Do analysts rate TKNO or NAUT?

Which has more volatility & risk, TKNO or NAUT?

Does the media refer more to TKNO or NAUT?

Do institutionals & insiders have more ownership in TKNO or NAUT?

Is TKNO or NAUT more profitable?

Which has higher earnings and valuation, TKNO or NAUT?

Summary

How does Nautilus Biotechnology compare to OmniAb?

Which has more volatility & risk, OABI or NAUT?

Do analysts prefer OABI or NAUT?

Is OABI or NAUT more profitable?

Which has higher valuation & earnings, OABI or NAUT?

Does the media refer more to OABI or NAUT?

Do institutionals and insiders have more ownership in OABI or NAUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools